万孚生物坚定“AI创新+国际化”双战略 引领2026发展新升级

Core Viewpoint - Guangzhou Wanfeng Biotechnology Co., Ltd. (Wanfeng Bio) anticipates a net profit attributable to shareholders of 46 million to 69 million yuan for the year 2025, amid significant adjustments in the IVD (in vitro diagnostics) sector, leading to a temporary decline in business performance [1] Domestic Market - The revenue from the colloidal gold and fluorescence product lines in the grassroots medical market has decreased, resulting in reduced profitability [1] - The launch of the FG-3000 gold standard reading instrument enhances operational efficiency in higher-tier hospitals, laying a solid hardware foundation for the digitalization and intelligence of gold standard business [1] - The introduction of new products such as the norovirus detection in the digestive tract business and the stabilization of terminal sales in the fluorescence business are noted, with significant growth in the grassroots public health glycosylated hemoglobin screening business [1] - The LA-1000 fluorescence level linking system has significantly improved automation and intelligence in emergency and outpatient services, while the LA-6000 intelligent laboratory assembly line has been successfully launched, with new projects like the six-item thrombosis test rapidly scaling up, resulting in a 40% year-on-year increase in terminal sales [1] Overseas Market - The overseas business continues to grow, with overseas revenue surpassing domestic revenue for the first time, providing crucial support for the company's sustainable growth [2] - The localization process in key countries has deepened, with an increasing share in small and medium laboratories in international markets [2] - In the North American market, the introduction of respiratory business has led to significant growth, with a long-term supply agreement signed with a major U.S. client for respiratory triad testing products, establishing a solid foundation for strategic layout in the U.S. respiratory infectious disease market [2] - By the end of 2025, the company will enter a new product harvest period, having obtained registration for several important single products, including a triad testing kit for respiratory syncytial virus, mycoplasma pneumonia, and adenovirus [2] Investment and Ecosystem Development - The company's direct investment in digital and AI pathology projects has seen rapid growth under the guidance of new national healthcare policies [3] - The "Intelligent Auxiliary Analysis Software for Coagulation Disorders" developed by the company has been selected for the "2025 Artificial Intelligence Medical Device Innovation Task" list, marking a substantial breakthrough in the strategic layout of AI-assisted diagnosis and laying a solid foundation for future clinical needs and commercialization [3] - In 2026, the company aims to leverage recovery in the domestic market, focusing on grassroots stability, and achieve rapid revenue improvement through the luminescence and molecular product lines [3] - The company will continue to expand its brand and channel advantages in overseas and North American markets to achieve high growth, while leveraging favorable policies to commercialize existing AI breakthroughs in pathology and clinical diagnosis [3]